Tukysa-G (Tucatinib Tablet) 150mg

Tukysa-G (Tucatinib) 150mg tablets are a targeted therapy for certain cancers. This oral medication is prescribed to slow disease progression in specific patient groups. Store at room temperature away from moisture and heat. Not all patients qualify for this treatment.

Strength

150mg

Pack Size

84s

Storage

Ambient

Manufacturer / TM Owner

Seagen

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Tucatinib 150mg tablets are primarily used to treat advanced or metastatic HER2-positive breast cancer in combination with other therapies. Patients often ask, what is Tucatinib used for beyond breast cancer, though its approved use is specific to HER2-positive cases. It belongs to a class of medicines that target cancer cells with HER2 protein overexpression.

Side Effects

Common effects of Tucatinib 150mg tablets may include fatigue, nausea, or diarrhea. Some users report reduced appetite or skin reactions. These effects vary by individual and are typically monitored by healthcare providers during treatment.

Precautions & Warnings

Keep Tucatinib 150mg tablets in their original packaging until use. Store at room temperature, away from direct sunlight and moisture. Always handle with dry hands and avoid crushing or splitting tablets unless advised by a healthcare professional.

Avoid Interactions

Tucatinib may interact with strong CYP3A inhibitors or inducers, affecting its effectiveness. Grapefruit products and certain supplements may also alter how the body processes this medication. Always inform your doctor about all medications and supplements you are taking.

Frequently Asked Questions

Tucatinib 150mg tablets are used to treat advanced or metastatic HER2-positive breast cancer in combination with other therapies.

Store at room temperature, away from moisture and heat. Keep the tablets in their original packaging until use.

Do not split or crush Tucatinib tablets unless instructed by your healthcare provider.

Yes, Tucatinib may interact with CYP3A inhibitors or inducers, as well as grapefruit products.

Common side effects may include fatigue, nausea, diarrhea, reduced appetite, or skin reactions.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.